Share on StockTwits

InterMune (NASDAQ:ITMN)‘s stock had its “overweight” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Tuesday. They currently have a $51.00 price objective on the stock, up from their previous price objective of $45.00. JPMorgan Chase & Co.’s price objective suggests a potential upside of 22.39% from the company’s current price.

InterMune (NASDAQ:ITMN) traded down 1.27% during mid-day trading on Tuesday, hitting $41.14. 817,289 shares of the company’s stock traded hands. InterMune has a one year low of $9.32 and a one year high of $42.68. The stock’s 50-day moving average is $36.04 and its 200-day moving average is $24.97. The company’s market cap is $4.068 billion.

InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the previous year, the company posted ($0.64) earnings per share. The company’s revenue for the quarter was up 188.6% on a year-over-year basis. Analysts expect that InterMune will post $-2.34 EPS for the current fiscal year.

In other InterMune news, CEO Daniel G. Welch unloaded 3,914 shares of the stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $39.19, for a total transaction of $153,389.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several other analysts have also recently commented on the stock. Analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Separately, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Finally, analysts at Leerink Swann upgraded shares of InterMune from a “market perform” rating to an “outperform” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $40.00.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.